Previously, several studies reported on potential biomarkers of ICI treatment for RCC, including high PD-L1 expression9, high tumor mutation burden (TMB)10, CD8-positive T-cell infiltration, genetic mutations such as PBRM111 and BRAF12, and the tumor microenvironment13. This evidence concerns the gene CD274 and neoplasm.